Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Items 301–400 of 876
Liu, R., Zhi, X., Zhou, Z., Zhang, H., Yang, R., Zou, T., & Chen, C. (2018) · Scientific Reports · doi:10.1038/s41598-018-19489-6 · Cited by 44
Ramaiah, M. J., Adusumilli, K., Chamarthy, S., & Angirekula, H. S. R. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01234-2 · Cited by 43
Rais, G., Raissouni, S. S., Aitelhaj, M., Rais, F., Naciri, S., Khoyaali, S., Abahssain, H., Bensouda, Y., Khannoussi, B. E., Mrabti, H. H., et al. (2012) · BMC Women s Health · doi:10.1186/1472-6874-12-35 · Cited by 43
PARP inhibitors – current status and the walk towards early breast cancer
Glendenning, J., & Tutt, A. N. J. (2011) · The Breast · doi:10.1016/s0960-9776(11)70288-0 · Cited by 43
Advancing Clinical Trials to Streamline Drug Development
Bates, S. E., Berry, D. A., Balasubramaniam, S., Bailey, S., LoRusso, P. M., & Rubin, E. H. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0039 · Cited by 43
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer
Parkes, E. E., & Kennedy, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0438 · Cited by 42
The evolving management of metastatic triple negative breast cancer
Malhotra, M. K., & Emens, L. A. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.005 · Cited by 42
Limited Overall Survival in Patients with Brain Metastases from Triple Negative Breast Cancer
Morris, P. G., Murphy, C. G., Mallam, D., Accordino, M. K., Patil, S., Howard, J., Omuro, A. M. P., Beal, K. P., Seidman, A. D., Hudis, C. A., et al. (2012) · The Breast Journal · doi:10.1111/j.1524-4741.2012.01246.x · Cited by 42
Wu, N., Zhang, J., Zhao, J., Mu, K., Zhang, J., Jin, Z., Yu, J., & Liu, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9290 · Cited by 41
Zhao, J., Mi, Y., & Feng, S. (2013) · Nanomedicine · doi:10.2217/nnm.13.73 · Cited by 41
Ramírez, L. V., Ramírez-Tortosa, M. C., Pérez-López, P., Granados-Principal, S. M., Battino, M. A., & Quiles, J. L. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.029 · Cited by 41
New targets for triple-negative breast cancer.
Herold, C. I., & Anders, C. K. (2013) · PubMed · Cited by 41
Jian, W., Xu, H., Chen, J., Xu, Z., Levitt, J. M., Stanley, J. A., Yang, E. S.-H., Lerner, S. P., & Sonpavde, G. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000114 · Cited by 40
Update on PARP1 inhibitors in ovarian cancer
Sessa, C. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr528 · Cited by 40
Sau, S., Mondal, S. K., Kashaw, S. K., Iyer, A. K., & Banerjee, R. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3084-z · Cited by 40
Emerging therapeutic modalities of PARP inhibitors in breast cancer
Wang, X., Shi, Y., Huang, D., & Guan, X. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.05.014 · Cited by 40
Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression
Rodríguez, M. I., Majuelos‐Melguizo, J., Martí, J. M., de Almodóvar, J. M. R., López‐Rivas, A., & Oliver, F. J. (2015) · Medicinal Research Reviews · doi:10.1002/med.21339 · Cited by 40
Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology
Stecklein, S. R., & Jensen, R. A. (2012) · Translational research · doi:10.1016/j.trsl.2012.01.022 · Cited by 40
Yardley, D. A., Brufsky, A., Coleman, R. E., Conte, P., Cortés, J., Glück, S., Nabholtz, J., O’Shaughnessy, J., Beck, R. M., Ko, A., et al. (2015) · Trials · doi:10.1186/s13063-015-1101-7 · Cited by 40
Self-citationNew drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance
Curigliano, G. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.06.006 · Cited by 41
Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Ang, J. E., Kaye, S. B., & Banerji, U. (2012) · Current Drug Targets · doi:10.2174/138945012803530062 · Cited by 39
Therapeutic Options for Metastatic Breast Cancer
Sambi, M., Qorri, B., Harless, W. W., & Szewczuk, M. R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_8 · Cited by 39
Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature
Landry, I., Sumbly, V., & Vest, M. (2022) · Cureus · doi:10.7759/cureus.21970 · Cited by 39
Targeted therapies in breast cancer
WICKI, A. N., & Rochlitz, C. F. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13550 · Cited by 38
Targeted Nanoparticles for Cancer Therapy
Blanco, M. D. V., Teijón, C., Olmo, R., & Teijo, J. M. (2012) · InTech eBooks · doi:10.5772/51382 · Cited by 40
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer
Luo, J., Jin, J., Yang, F., Sun, Z., Zhang, W., Shi, Y., Xu, J., & Guan, X. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.16176 · Cited by 38
Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics
Yang, Z., Waldman, A. S., & Wyatt, M. D. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.022 · Cited by 37
Radovich, M., Clare, S. E., Atale, R. V., Pardo, I., Hancock, B. A., Solzak, J. P., Kassem, N., Mathieson, T., Storniolo, A. M., Rufenbarger, C., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2780-y · Cited by 38
EIERMANN, W., Bergh, J. C. S., Cardoso, F., Conte, P., Crown, J. P., Curtin, N. J., Gligorov, J., Gusterson, B. A., Joensuu, H., Linderholm, B. K., et al. (2011) · The Breast · doi:10.1016/j.breast.2011.09.006 · Cited by 38
Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
Mancini, P., Angeloni, A., Risi, E., Orsi, E., & Mezi, S. (2014) · Cancers · doi:10.3390/cancers6042187 · Cited by 37
Shotgun proteomics of archival triple‐negative breast cancer samples
Gámez‐Pozo, A., Ferrer, N. I., Ciruelos, E., López‐Vacas, R., García, F., Espinosa, E., & Vara, J. Á. F. (2013) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201200048 · Cited by 36
nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer
Glück, S. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.02.001 · Cited by 35
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer
Saijo, N. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.02.004 · Cited by 35
Hodge, D. Q., Cui, J., Gamble, M. J., & Guo, W. (2018) · Scientific Reports · doi:10.1038/s41598-018-19364-4 · Cited by 35
Treatment of ovarian cancer beyond chemotherapy: Are we hitting the target?
Garces, A. I., Dias, M. S. F., Paulino, E., Ferreira, C. G., & de Melo, A. C. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2581-y · Cited by 35
Başer, O., Wei, W., Henk, H. J., Teitelbaum, A. H., & Xie, L. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.628649 · Cited by 35
Giacchetti, S., Porcher, R., Lehmann‐Che, J., Hamy, A., de Roquancourt, A., Cuvier, C., Cottu, P. H., Bertheau, P., Albiter, M., Bouhidel, F. A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.81 · Cited by 35
Causal Network Models for Predicting Compound Targets and Driving Pathways in Cancer
Jaeger, S. A., Min, J., Nigsch, F., Camargo, M. L., Hutz, J., Cornett, A., Cleaver, S. H., Buckler, A., & Jenkins, J. L. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114522690 · Cited by 35
Novello, S., Besse, B., Felip, E., Barlési, F., Mazières, J., Zalcman, G., von Pawel, J., Reck, M., Cappuzzo, F., Ferry, D., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu384 · Cited by 35
Decision Making from Phase II to Phase III and the Probability of Success: Reassured by “Assurance”?
Carroll, K. J. (2013) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2013.813527 · Cited by 35
Liu, X., Wu, K., Zheng, D., Luo, C., Fan, Y., Zhong, X., & Zheng, H. Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.742139 · Cited by 34
Xie, X., Lee, J., Liu, H., Pearson, T., Lu, A., Tripathy, D., Devi, G. R., Bartholomeusz, C., & Ueno, N. T. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1160 · Cited by 34
Clinical trials in triple negative breast cancer
Reeder-Hayes, K. E., Carey, L., & Sikov, W. M. (2011) · Breast Disease · doi:10.3233/bd-2010-0310 · Cited by 34
Therapeutic Targeting of Cancer Stem Cells
Maugeri‐Saccà, M., Zeuner, A., & Maria, R. D. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00010 · Cited by 34
New treatment strategies for patients with triple-negative breast cancer
Liedtke, C., & Rody, A. (2014) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000137 · Cited by 34
Chen, T., Liu, C., Lu, H., Yin, M., Shao, C., Hu, X., Wu, J., & Wang, Y. (2017) · Tumor Biology · doi:10.1177/1010428317713390 · Cited by 34
Multi-gene Panel Testing in Breast Cancer Management
Fountzilas, C. K., & Kaklamani, V. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-70197-4_8 · Cited by 34
Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer
Glénisson, M., Vacher, S., Callens, C., Susini, A., Cizeron-Clairac, G., Scodan, R. L., Meseure, D., Lerebours, F., Spyratos, F., Lidereau, R., et al. (2012) · Genes & Cancer · doi:10.1177/1947601912449832 · Cited by 34
Platinum-based chemotherapy in triple-negative advanced breast cancer
Villarreal-Garza, C., Khalaf, D., Bouganim, N., Clemons, M., Peña-Curiel, O., Baez-Revueltas, B., Kiss, A., Kassam, F., Enright, K., Verma, S., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3033-4 · Cited by 33
Brodowicz, T., Láng, I., Kahán, Z., Greil, R., Beslija, S., Stemmer, S. M., Kaufman, B., Petruzelka, L. B., Eniu, A. E., Anghel, R. M., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.504 · Cited by 33
Cavone, L., & Chiarugi, A. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.10.002 · Cited by 33
Molecular Predictors of Response to Therapy for Breast Cancer
Galanina, N., Bossuyt, V., & Harris, L. N. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212dee3 · Cited by 33
Neoadjuvant chemotherapy in breast cancer—insights from the German experience
von Minckwitz, G. (2012) · Breast Cancer · doi:10.1007/s12282-012-0393-7 · Cited by 33
Olaparib for the treatment of breast cancer
Robert, M., Frenel, J., Gourmelon, C., Patsouris, A., Augereau, P., & Campone, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1318847 · Cited by 33
Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer
Scalise, C. B., Soloff, A. C., Ethier, S. P., & Yeh, E. S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.008 · Cited by 33
Cowherd, S., Miller, L. D., Melin, S. A., Akman, S. A., Isom, S. P., Cole, J., Pullikuth, A., & Lawrence, J. A. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1026481 · Cited by 33
Recurrent Prostate Cancer Genomic Alterations Predict Response to Brachytherapy Treatment
Fontugne, J., Lee, D. C., Cantaloni, C., Barbieri, C. E., Caffo, O., Hanspeter, E., Mazzoleni, G., Palma, P. D., Rubin, M. A., Fellin, G., et al. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-1180 · Cited by 33
The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
Narrandes, S., Huang, S., Murphy, L. C., & Xu, W. W. (2018) · BMC Cancer · doi:10.1186/s12885-017-3939-4 · Cited by 32
Quist, J., Mirza, H., Cheang, M. C. U., Telli, M. L., O’Shaughnessy, J., Lord, C. J., Tutt, A. N. J., & Grigoriadis, A. E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0243 · Cited by 32
Self-citationMakhale, A., Nanayakkara, D. M., Raninga, P. V., Khanna, K. K., & Kalimutho, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115782 · Cited by 32
CMF revisited in the 21st century
Munzone, E., Curigliano, G., Burstein, H. J., Winer, E. P., & Goldhirsch, A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr309 · Cited by 32
Jiang, L., Lee, S. C., & Ng, T. C. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00859 · Cited by 32
National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer
George, T. J., Franke, A. J., Chakravarthy, A. B., Das, P., Dasari, A. N., El‐Rayes, B. F., Hong, T. S., Kinsella, T. J., Landry, J. C., Lee, J. J., et al. (2019) · Cancer · doi:10.1002/cncr.32150 · Cited by 32
MYC, PARP1, and Chemoresistance: BIN There, Done That?
Ganesan, S. (2011) · Science Signaling · doi:10.1126/scisignal.2001946 · Cited by 32
Gonçalvès, A., Sabatier, R., Charafe‐Jauffret, E., Gilabert, M., Provansal, M., Tarpin, C., Extra, J.-M., Viens, P., & Bertucci, F. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1740 · Cited by 31
Present Status and Problems on Molecular Targeted Therapy of Cancer
Saijo, N. (2012) · Cancer Research and Treatment · doi:10.4143/crt.2012.44.1.1 · Cited by 31
Zhang, N., Wang, D., Jing, X., Yang, T., Yang, H., & Meng, L. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00569 · Cited by 30
Zeng, Y., Song, G., Zhang, S., Li, S., Meng, T., Yuan, H., & Hu, F. (2023) · Biomacromolecules · doi:10.1021/acs.biomac.3c00523 · Cited by 30
An overview of triple negative breast cancer for surgical oncologists
Sharma, S., Barry, M., Gallagher, D. J., Kell, M., & Sacchini, V. (2015) · Surgical Oncology · doi:10.1016/j.suronc.2015.06.007 · Cited by 30
Liedtke, C., & Kiesel, L. (2012) · Maturitas · doi:10.1016/j.maturitas.2012.08.006 · Cited by 30
Saba, C., Paoloni, M. C., Mazcko, C. N., Kisseberth, W. C., Burton, J. H., Smith, A. N., Wilson-Robles, H. M., Allstadt, S. D., Vail, D. M., Henry, C. J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149194 · Cited by 30
Expression of the BAD pathway is a marker of triple-negative status and poor outcome
Boac, B. M., Abbasi, F., Ismail-Khan, R. R., Xiong, Y., Siddique, A., Park, H., Han, M., Saeed‐Vafa, D., Soliman, H. H., Henry, B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53695-0 · Cited by 30
Emerging Trends in the Treatment of Triple-Negative Breast Cancer in Canada: A Survey
Verma, S., Provencher, L., & Dent, R. A. (2011) · Current Oncology · doi:10.3747/co.v18i4.913 · Cited by 30
Poly(ADP-ribose) polymerase inhibitors as cancer therapy
Hilton, J. F., Hadfield, M. J., Tran, M.-T., & Shapiro, G. I. (2013) · Frontiers in bioscience · doi:10.2741/4188 · Cited by 29
Recent developments in decarboxylative C(aryl)–X bond formation from (hetero)aryl carboxylic acids
Sharma, R., & Yadav, M. R. (2021) · Organic & Biomolecular Chemistry · doi:10.1039/d1ob00675d · Cited by 29
Cavin3 released from caveolae interacts with BRCA1 to regulate the cellular stress response
McMahon, K., Stroud, D. A., Gambin, Y., Tillu, V. A., Bastiani, M., Sierecki, E., Polinkovsky, M. E., Hall, T. E., Gomez, G. A., Wu, Y., et al. (2021) · eLife · doi:10.7554/elife.61407 · Cited by 29
Pellicano, F., Mukherjee, L., & Holyoake, T. L. (2014) · Stem Cells · doi:10.1002/stem.1678 · Cited by 29
Zhang, J., Wang, L., Wang, Z., Hu, X., Wang, B., Cao, J., Lv, F., Zhen, C., Zhang, S., & Shao, Z. (2015) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.986973 · Cited by 29
Novel therapeutic strategies for patients with triple-negative breast cancer
Zhang, J., Liu, J., Wang, Y., & Zhang, B. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s105716 · Cited by 29
Patient-Level DNA Damage Repair Pathway Profiles and Anti-Tumor Immunity for Gastric Cancer
Lou, S., Wang, Y., Zhang, J., Yin, X., Zhang, Y., Wang, Y., & Xue, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806324 · Cited by 28
Potential molecular mechanisms and clinical progress in liver metastasis of breast cancer
Liu, H., Li, X., Li, H., Feng, L., Sun, G., Sun, G., Wu, L., Hu, Y. H., Liu, L., & Wang, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112824 · Cited by 28
Yan, Q., Ding, J., Khan, S. J., Lawton, L. N., & Shipp, M. A. (2023) · iScience · doi:10.1016/j.isci.2023.106444 · Cited by 28
Fukasawa, K., Kagaya, S., Maruyama, S., Kuroiwa, S., Masuda, K., Kameyama, Y., Satoh, Y., Akatsu, Y., Tomura, A., Nishikawa, K., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0158 · Cited by 28
Kim, K. M., Moon, Y. J., Park, S., Park, H. J., Wang, S. I., Park, H. S., Lee, H., Kwon, K. S., Moon, W. S., Lee, D. G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163193 · Cited by 28
Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
Gregório, A. C., Lacerda, M., Figueiredo, P., Simões, S., Dias, S., & Moreira, J. N. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0307-2 · Cited by 28
Ha, G., Kim, D., Breuer, E.-K. Y., & Kim, C. K. (2018) · Anticancer Research · doi:10.21873/anticanres.12352 · Cited by 28
Kalra, M., Tong, Y., Jones, D. R., Walsh, T., Danso, M. A., Ma, C. X., Silverman, P., King, M., Badve, S., Perkins, S. M., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00240-w · Cited by 28
Patterson, M. J., Sutton, R. E., Forrest, I., Sharrock, R., Lane, M., Kaufmann, A., O'Donnell, R. L., Edmondson, R. J., Wilson, B. T., & Curtin, N. J. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.261 · Cited by 28
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
Thigpen, J. T. (2011) · Yearbook of Oncology · doi:10.1016/j.yonc.2011.07.022 · Cited by 28
Implications of genomic instability in the diagnosis and treatment of breast cancer
Wiecheć, E. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.21 · Cited by 27
Targeted Therapy for EWS-FLI1 in Ewing Sarcoma
Gong, H., Xue, B., Ru, J., Pei, G., & Li, Y. (2023) · Cancers · doi:10.3390/cancers15164035 · Cited by 27
Nanoparticle-Mediated Measurement of Target–Drug Binding in Cancer Cells
Ullal, A. V., Reiner, T., Yang, K. S., Gorbatov, R., Min, C., Issadore, D., Lee, H., & Weissleder, R. (2011) · ACS Nano · doi:10.1021/nn203450p · Cited by 27
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers
Stanley, J. A., Klepczyk, L. C., Keene, K. S., Wei, S., Li, Y., Forero, A., Grizzle, W. E., Wielgos, M. E., Brazelton, J. D., LoBuglio, A. F., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3359-6 · Cited by 27
Targeting Angiogenesis in Metastatic Breast Cancer
Reddy, S. M., Raffin, M., & Kaklamani, V. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0043 · Cited by 27
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors
Leonetti, C., Biroccio, A., Graziani, G., & Tentori, L. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277403 · Cited by 27
Pistollato, F., Bernasconi, C., McCarthy, J., Campia, I., Desaintes, C., Wittwehr, C., Deceuninck, P., & Whelan, M. (2020) · Animals · doi:10.3390/ani10071194 · Cited by 27
Węsierska‐Gądek, J., Mauritz, M., Mitulović, G., & Cupo, M. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25229 · Cited by 27
Therapeutic potential of PARP inhibitors for metastatic breast cancer
Irshad, S., Ashworth, A., & Tutt, A. N. J. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.52 · Cited by 26
Trial watch – inhibiting PARP enzymes for anticancer therapy
Sistigu, A., Manic, G., Obrist, F., & Vitale, I. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1053594 · Cited by 26
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.